Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Buy” by the fifteen analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $85.80.
Several analysts recently commented on the company. ValuEngine upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. BidaskClub cut Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. TheStreet upgraded Nektar Therapeutics from a “d” rating to a “c” rating in a research report on Wednesday, August 8th. HC Wainwright set a $54.00 target price on Nektar Therapeutics and gave the company a “hold” rating in a research report on Friday, August 10th. Finally, William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a research report on Thursday, August 9th.
In other news, Director Jeffrey Robert Ajer sold 6,750 shares of Nektar Therapeutics stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $56.76, for a total transaction of $383,130.00. Following the transaction, the director now directly owns 15,750 shares in the company, valued at approximately $893,970. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Dennis L. Winger sold 15,000 shares of Nektar Therapeutics stock in a transaction on Friday, August 17th. The shares were sold at an average price of $59.62, for a total value of $894,300.00. Following the transaction, the director now owns 57,750 shares in the company, valued at $3,443,055. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 96,000 shares of company stock worth $5,825,680. 4.31% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of NKTR. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Nektar Therapeutics during the 2nd quarter valued at $137,000. Flagship Harbor Advisors LLC acquired a new position in shares of Nektar Therapeutics during the 2nd quarter valued at $142,000. Raymond James Financial Services Advisors Inc. increased its position in shares of Nektar Therapeutics by 68.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 4,290 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,747 shares during the period. Gabelli Funds LLC acquired a new position in shares of Nektar Therapeutics during the 3rd quarter valued at $213,000. Finally, Meristem LLP acquired a new position in shares of Nektar Therapeutics during the 2nd quarter valued at $225,000. Institutional investors own 91.94% of the company’s stock.
Shares of NASDAQ NKTR traded down $1.64 during mid-day trading on Monday, hitting $39.05. The company had a trading volume of 1,857,681 shares, compared to its average volume of 2,309,453. The company has a market cap of $6.67 billion, a price-to-earnings ratio of 7.80 and a beta of 2.91. Nektar Therapeutics has a 12 month low of $23.20 and a 12 month high of $111.36. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.11. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.03 billion. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. The business’s revenue was up 3043.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.39) EPS. As a group, equities analysts forecast that Nektar Therapeutics will post 3.57 earnings per share for the current fiscal year.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Further Reading: What is the balance sheet?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.